Introduction: Iron deficiency (ID) is a common comorbidity in chronic heart failure patients that can be routinely diagnosed by serum laboratorial tests showing reduced ferritin and/or transferrin saturation (TSAT) levels. However, it is not clear the impact on survival of different biochemical tests widely used for ID diagnosis. Hypothesis:
Mortality Risk in Pulmonary Embolism with Right and Left Heart Failure at a Community Teaching Hospital
Uri Goldberg, Sameera Ishtiaq, Mohamed Alibakhiet, Wazhma Nasiri, Rajat Mukherji, Madhumati Kalavar; Kingsbrook Jewish Medical Center, Brooklyn, NY Objective: Though venous thromboembolism (VTE) is thought to be underdiagnosed in the general population, roughly 900,000 people are estimated to be affected by VTE each year in the U.S. According to CDC figures, VTE accounts for roughly 60,000 to 100,000 annual deaths. Recent research has recommended the inclusion of additional metrics, such as cardiac dysfunction, to current pulmonary embolism (PE) risk stratification scores. We have sought to evaluate the mortality risk of PE in patients with right and/or left heart failure. Methods: This is an ongoing retrospective cohort study examining the mortality risk of PE with comorbid cardiac dysfunction among patients admitted to an urban community teaching hospital between January 2011 and March 2015. Radiological findings for patients who underwent computed tomography angiography (CTA) and echocardiogram were reviewed. Mortality risk was stratified by presence or absence of right ventricular (RV) dysfunction, left heart failure with reduced ejection fraction (HFrEF), and left heart failure with preserved ejection fraction (HFpEF). Results: Results of 1777 CTAs were reviewed of which 160 demonstrated a positive finding of PE: 103 women (64.4%) and 57 men (35.6%). Echocardiography was performed on 111 of the 160 patients who were found to have PE. Of the evaluated patients, 9 expired within one year of discharge (8.1%). Among those patients who lived at least one year past discharge, echocardiography was found to be normal in 55 patients (53.9%). Of the remaining surviving patients, 40 were found to have HFpEF (39.2%), 14 were found to have HFrEF (13.7%), and 6 were found to have RV dysfunction (5.9%). Of the 9 patients who expired within one year of discharge, echocardiography was found to be normal in 1 patient (11.1%). The remaining patients demonstrated HFpEF (55.6%), HFrEF (44.4%), and RV dysfunction (33.3%). Discussion: The combination of high mortality and rapid-though often overlooked-onset make VTE a uniquely vexing condition. The Simplified Pulmonary Embolism Severity Index (sPESI) evaluates 30-day PE outcomes including mortality, recurrent VTE, and non-fatal hemorrhage by measuring such metrics as age, cancer history, cardiopulmonary disease history, heart rate, systolic blood pressure, and oxygen saturation. Though effective in identifying low-risk patients, the positive predictive value of risk stratification models such as sPESI in the identification of high-risk patients may improve with the use of echocardiogram to evaluate for right and left heart failure.
Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate in Vha Heart Failure Patients by Ethnicity
Boback Ziaeian 1 , Gregg C. Fonarow 2 , Paul Heidenreich 3 ; 1 UCLA-VA, Los Angeles, CA; 2 UCLA, Los Angeles, CA; 3 VA Palo Alto, Palo Alto, CA Background: Among African American patients with heart failure (HF) with reduced ejection fraction (HFrEF), the combination of hydralazine and isosorbide dinatrate (H-ISDN) in addition to usual care was found to improve quality of life, lower HF hospitalization and mortality rates in the A-HEFT randomized control trial. Few studies have evaluated the effectiveness in a real world setting. Methods: VA patients with a primary HF admission between 2007 to 2013 were screened for inclusion in an observational cohort. Inclusion criteria included African American ethnicity, left ventricular ejection fraction <40%, and received regular medications through the VA pharmacy. Patients were excluded if they had contraindications to receiving H-ISDN, a creatinine greater 2.0, or intolerance to angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB). Hazard ratios (HR) were calculated for patients who received H-ISDN 6 months prior to admission compared to those that did not receive H-ISDN using inverse probability weighting of propensity scores and a time to death analysis with 18 months of follow-up. Propensity scores were generated using patient characteristics, vitals, lab values, and hospital characteristics. Results: The final cohort included 5168 African American HF patients (age 65.19) with 15.2% treated with H-ISDN prior to index admission. After 18 months of follow-up from index admission, there were 1275 reported deaths (24.7%). The unadjusted HR was 0.88, (P = .11), adjusted HR using inverse probability weighting of propensity scores were 0.85, (P = .006). Adjusted mortality at 18 months was 22.1% for H-ISDN treatment and 25.2% for untreated (P = .009). Conclusions: H-ISDN remains underutilized in African American patients with HFrEF for unclear reasons. In this observational cohort, we find a significant mortality advantage associated with H-ISDN use in African American HFrEF patients at 18 months when adjusting for patient and hospital factors using an inverse probability weighted propensity score model. The 20 th Annual Scientific Meeting • HFSA S93
